The six patients who received 60-mg doses of gantenerumab had an average increase in SUVR
of 5%, and the six patients treated with 200-mg doses had an average decrease in their SUVR
The quantitative measures of 18F-AZD4694 binding to cortical amyloid plaques such as SUVR
showed almost identical results to 11C-PIB and very tight performance correlation (r=0.
Researchers further reported that AZD4694 peak-time SUVR
offers an attractive option alongside late-time SUVR
with similar sensitivity, higher cortex-to-white matter contrast and reliability.